AlphAIAlphAI — Financial news for AI agents
Stock TitanAPR 272 min read$HRTX

Heron sets May 11 webcast for Q1 results and business updates

Heron Therapeutics (Nasdaq: HRTX) announced it will report its first-quarter 2026 financial results and discuss business highlights on Monday, May 11, 2026, at 8:30 a.m. ET. The event will include a conference call and live webcast accessible through registration on the company's investor relations website, where an archive will also be available for 60 days. Investors are advised to register and dial in 15 minutes early to avoid delays.

Original reporting
Stock Titan
Published Apr 27, 2026, 9:34 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Apr 27, 2026, 10:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Heron sets May 11 webcast for Q1 results and business updates — source image
Source · Stock Titan
Decision brief

The 30-second read

$HRTXNeutralMed
01

Why it matters

Earnings results are likely to influence short-term trading activity, with the possibility of increased volatility around the event.

02

Market read

The event is highly relevant for investors and traders focusing on biotech and life sciences sectors, with potential ripple effects on related stocks.

03

What to watch

Potential regulatory developments or pipeline updates could overshadow earnings results and influence stock movement.

Timing: High, as the event is scheduled for May 11, 2026, and traders can position accordingly.

Background

Heron Therapeutics specializes in developing and commercializing therapies for cancer and other serious conditions. The upcoming earnings report will provide insights into its financial health and pipeline progress.

Company-level read

Ticker impact

$HRTXNeutralMedium confidence
Context

The upcoming Q1 2026 earnings report is a significant event for Heron Therapeutics, potentially impacting the stock's short-term price movement.

Expected impact

Potential for increased volatility around the event; stock may experience a short-term move in either direction depending on results and guidance.

Evidence & confidence

Earnings reports typically lead to increased trading activity; however, without current stock price and analyst consensus data, the precise impact remains uncertain.

Market effects

Sector

Positive earnings could boost investor confidence in the biotech/life sciences sector, potentially lifting sector indices.

Regional

Limited regional impact; primarily affecting US-based biotech stocks.

Global

Minimal, unless results significantly outperform or underperform expectations, influencing global biotech sentiment.

Counterpoint

What could challenge this read

Disappointing earnings or guidance could lead to a sharp decline, suggesting caution in overly optimistic positioning.

Key entities

  • Company
    Heron Therapeutics

    A biotech company focused on cancer and other serious conditions.

Read at source← All news

Related articles

AUG 29
$FULCMed

Why Did FULC, MVIS, HRTX Stocks Plunge To 52-Week Lows Today?

Fulcrum Therapeutics (FULC) fell 51% to a 52-week low of $2.9 after halting development of its lead sickle cell disease treatment due to FDA cancer risk concerns. Heron Therapeutics (HRTX) dropped 45% to $0.44 following a court ruling invalidating key patents for CINVANTI. MicroVision (MVIS) declined 32% to $0.4 after proposing a reverse stock split to meet Nasdaq requirements.

stocktwits.com2 min
AUG 17
$HRTXMedAI 8/10

Heron (HRTX) Q2 2026 Earnings Call Transcript

Heron Therapeutics (HRTX) reported Q2 2026 net revenue of $37.7M, up from $34.7M in Q1 but below expectations. CINVANTI was $21.8M, ZYNRELEF $11.1M (+35% YoY), and APONVIE $4.2M (+74% YoY). After a June patent ruling, the company amended its Hercules credit facility, resetting covenants through 2027 and reducing principal. It withdrew full-year 2026 guidance.

yahoo.com7 min
AUG 10
$HRTXMedAI 8/10

Heron Therapeutics Q2 Earnings Call Highlights

Heron Therapeutics (NASDAQ:HRTX) reported Q2 sales of about $4.2M for APONVIE, up 26% QoQ and 74% YoY, and $21.8M for CINVANTI, down about 10% YoY. SUSTOL contributed $0.5M as wind-down continued. Heron posted a Q2 net loss of $5.5M, gross margin 69.3%, and ended with $42.7M cash equivalents. It amended its Hercules credit facility with a $13.5M principal reduction and potential $4M more, and withdrew 2026 guidance.

yahoo.com6 min
AUG 10
$HRTXMed

Heron Therapeutics Announces Second Quarter 2026 Financial Results

HERON THERAPEUTICS, INC. /DE/ (HRTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Heron Therapeutics Announces Second Quarter 2026 Financial Results - Q2 2026 net revenue of $37.7 million, up 9% from the first quarter of 2026; ZYNRELEF ® net revenue grew 35% and APONVIE ® net revenue grew 74% year-over-year - Amended credit facility with Hercules

SEC EDGAR 8-K6 min
SEP 29
$LMTMedAI 8/10

Lockheed Martin (LMT) Secures $298 Million in New Defense Contra

Lockheed Martin (LMT) announced $298M in contract modifications for U.S. Navy and Japan's defense systems. The company offers a 2.63% dividend yield with a 50% payout ratio and 5.4% 3-year growth. Its GF Value suggests a 9.4% undervaluation. LMT has a GF Score of 89/100, with strong profitability and valuation metrics. Institutional guru ownership is robust, but insider activity shows net selling.

gurufocus.com2 min
SEP 29
$LMTMedAI 9/10

Lockheed Martin (LMT) Secures $245M Contract Modification to Exp

Lockheed Martin (LMT) received a $245M contract modification to expand production of F/A-18E/F Infrared Search and Track Block II systems for the U.S. Navy and Royal Australian Air Force. The company offers a 2.63% dividend yield, a 50% payout ratio, and a 3-year dividend growth rate of 5.4%. LMT's stock is trading 9.4% below its GF Value™ of $565.64, with a GF Score™ of 89/100. Institutional investors show mixed sentiment, while insiders have sold $4.0M in shares over the past year.

gurufocus.com2 min